Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Healthcare Biotechnology
Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Liminal BioSciences Inc.
Bullboard Posts
User Avatar Image
(0)
•••
Post by CMaxon Jan 18, 2017 3:11pm
331 Views
Post# 25724376

Patent

PatentThis stuff is way over my head but here's the latest patent granted to Prometic on january 3rd, 2017.

Treatment of kidney diseases.

https://patents.justia.com/patent/9532962

Patent History

Patent number: 9532962
Type: Grant 
Filed: Nov 3, 2008
Date of Patent: Jan 3, 2017
Patent Publication Number: 20100286269
Assignee: PROMETIC PHARMA SMT LIMITED (Cambridge) 
Inventors: Vincent Pichette (St. Hyacinthe), Francois Leblond (Le Gardeur), Mouna Lagraoui (Laval), Lyne Gagnon (Laval) 
Primary Examiner: Leslie A. Royds Draper 
Application Number: 12/740,700

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities